about
NCAM(CD56) and RUNX1(AML1) are up-regulated in human ischemic cardiomyopathy and a rat model of chronic cardiac ischemia.Novel RUNX1 isoforms determine the fate of acute myeloid leukemia cells by controlling CD56 expression.Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.Chromosome 6 suffers frequent and multiple aberrations in thymoma.Lymphangiosis carcinomatosa in squamous cell carcinomas of larynx and hypopharynx--value of conventional evaluation and additional immunohistochemical staining of D2-40Specific detection of CD56 (NCAM) isoforms for the identification of aggressive malignant neoplasms with progressive development.Expression of p-AKT characterizes adenoid cystic carcinomas of head and neck with a higher risk for tumor relapses.Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trialsCombined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma.A new tumor-specific variant of GRP78 as target for antibody-based therapy.Expression of CD56 isoforms in primary and relapsed adult granulosa cell tumors of the ovary.
P50
Q30978186-D723515A-2A24-4008-9D47-CC9DE60608A0Q33281984-4FB3CACE-0881-4224-BD45-94D6ADAC28D0Q34534439-90B3BE46-0F28-4515-8D8C-082CB1871132Q34611141-4C9E7EDA-5F17-43A5-A282-6FDE14DDC425Q34622522-AF83CCBE-4FEF-486D-AF1C-1BED88CD6C0FQ34623144-01C28CDF-7636-4E02-B9BD-0C15730BF22BQ35789302-6DE79447-4CE5-4F77-8068-761BC7890BD1Q37121546-6070702D-46E2-4D67-87E5-4929A9D7E29DQ37164501-53B0513B-B3E6-4281-B096-5E10E810970BQ37246387-3229D454-2E5A-4DDE-B980-3E455DA033CFQ37406798-B541A746-85B8-49A0-A56B-02E074E9AB08Q39960098-3D0E9519-783C-481F-BC73-2FE6A4BAA9FCQ40014019-D0E018A1-87C8-47FF-A63A-B2F011D09751Q40618662-849E97D0-8D22-4A8C-ADA0-D67FD149F8DC
P50
description
onderzoeker
@nl
name
Hans-Konrad Müller-Hermelink
@ast
Hans-Konrad Müller-Hermelink
@en
Hans-Konrad Müller-Hermelink
@sl
type
label
Hans-Konrad Müller-Hermelink
@ast
Hans-Konrad Müller-Hermelink
@en
Hans-Konrad Müller-Hermelink
@sl
prefLabel
Hans-Konrad Müller-Hermelink
@ast
Hans-Konrad Müller-Hermelink
@en
Hans-Konrad Müller-Hermelink
@sl